GLUE vs. WVE, APGE, EVO, IRON, ARQT, AMPH, IMCR, AAPG, KNSA, and DYN
Should you be buying Monte Rosa Therapeutics stock or one of its competitors? The main competitors of Monte Rosa Therapeutics include Wave Life Sciences (WVE), Apogee Therapeutics (APGE), Evotec (EVO), Disc Medicine (IRON), Arcutis Biotherapeutics (ARQT), Amphastar Pharmaceuticals (AMPH), Immunocore (IMCR), Ascentage Pharma Group International (AAPG), Kiniksa Pharmaceuticals (KNSA), and Dyne Therapeutics (DYN). These companies are all part of the "pharmaceutical products" industry.
Monte Rosa Therapeutics vs.
Monte Rosa Therapeutics (NASDAQ:GLUE) and Wave Life Sciences (NASDAQ:WVE) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their analyst recommendations, earnings, institutional ownership, risk, dividends, media sentiment, valuation, profitability and community ranking.
Monte Rosa Therapeutics has a beta of 1.46, indicating that its share price is 46% more volatile than the S&P 500. Comparatively, Wave Life Sciences has a beta of -1.09, indicating that its share price is 209% less volatile than the S&P 500.
Monte Rosa Therapeutics currently has a consensus target price of $14.00, indicating a potential upside of 125.08%. Wave Life Sciences has a consensus target price of $22.22, indicating a potential upside of 99.66%. Given Monte Rosa Therapeutics' higher probable upside, equities research analysts plainly believe Monte Rosa Therapeutics is more favorable than Wave Life Sciences.
Wave Life Sciences has higher revenue and earnings than Monte Rosa Therapeutics. Wave Life Sciences is trading at a lower price-to-earnings ratio than Monte Rosa Therapeutics, indicating that it is currently the more affordable of the two stocks.
Wave Life Sciences received 349 more outperform votes than Monte Rosa Therapeutics when rated by MarketBeat users. Likewise, 67.85% of users gave Wave Life Sciences an outperform vote while only 46.67% of users gave Monte Rosa Therapeutics an outperform vote.
Monte Rosa Therapeutics has a net margin of 0.00% compared to Wave Life Sciences' net margin of -66.50%. Monte Rosa Therapeutics' return on equity of -62.68% beat Wave Life Sciences' return on equity.
80.0% of Monte Rosa Therapeutics shares are held by institutional investors. Comparatively, 89.7% of Wave Life Sciences shares are held by institutional investors. 6.5% of Monte Rosa Therapeutics shares are held by insiders. Comparatively, 29.1% of Wave Life Sciences shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.
In the previous week, Wave Life Sciences had 2 more articles in the media than Monte Rosa Therapeutics. MarketBeat recorded 3 mentions for Wave Life Sciences and 1 mentions for Monte Rosa Therapeutics. Monte Rosa Therapeutics' average media sentiment score of 1.90 beat Wave Life Sciences' score of 1.34 indicating that Monte Rosa Therapeutics is being referred to more favorably in the media.
Summary
Wave Life Sciences beats Monte Rosa Therapeutics on 11 of the 18 factors compared between the two stocks.
Get Monte Rosa Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for GLUE and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Monte Rosa Therapeutics Competitors List
Related Companies and Tools
This page (NASDAQ:GLUE) was last updated on 2/22/2025 by MarketBeat.com Staff
